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Background.T os t u d yt h ee ﬀects of an aqueous extract of date fruit (Phoenix dactylifera L. Arecaceae) diet on diabetic
polyneuropathy (DPN) in streptozotocin- (STZ-) induced diabetic rats. Methods. The eﬀects of a date fruit extract (DFE) diet on
diabetic neuropathy in STZ-induced diabetic rats were evaluated and compared with a nondiabetic control group, diabetic control
group (sham), and vehicle group with respect to the following parameters: open ﬁeld behavioral test, motor nerve conduction
velocity (MNCV), and morphological observations. Results. In the model of STZ-induced of diabetic neuropathy, chronic
treatment for 6 weeks with DFE counteracted the impairment of the explorative activity of the rats in an open ﬁeld behavioral
test and of the conduction velocity of the sciatic nerve (MNCV). In addition, pretreatment with DFE signiﬁcantly reversed each
nerve diameter reduction in diabetic rats. Conclusion. DFE treatment shows eﬃcacy for preventing diabetic deterioration and for
improving pathological parameters of diabetic neuropathy in rats, as compared with control groups.
1.Introduction
Diabetes mellitus is a chronic metabolic disorder that leads
to long-term complications aﬀecting some tissues such
as heart, kidney, retina, and peripheral nerves. Peripheral
neuropathyisoneofthemostfrequentandpotentiallysevere
complicationsofdiabetes,leadingtopain,skinulcers,muscle
weakness, loss of independence, and overall impairment
of the patient’s quality of life. Diabetic neuropathy is a
multifaceted complication of both type I and II diabetes,
withanestimatedprevalencebetween50and90%depending
on the duration of diabetes and involves a spectrum of
functional and structural changes in peripheral nerves
[1]. Early disorders of nerve function include slowing in
nerve conduction velocity followed by axonal degeneration,
paranodal demyelination and loss of myelinated ﬁbers [2].
Experimental DPN shares a number of features with human
DPN, such as the structural, functional, and biochemical
alterations [3, 4].
At the pathological level, the decrease of intraepidermal
nerve ﬁber density in diabetics with symptoms of neu-
ropathycorrelateswithelectrophysiologicalandpsychophys-
ical Abnormalities [5–7]. Several interactive pathogenetic
mechanisms of DPN have been identiﬁed in both human
and murine models and persistent hyperglycaemia has been
regarded as a primary risk factor for neuropathy [8].
Long-termhyperglycaemialeadstosubsequentenhanced
oxidative stress, increased aldose reductase activity, accu-
mulation of advanced glycation endproducts, and decreased
Na+,K +-ATPase activity [9–12]. Diabetic neuropathy is also
thought to develop as a result of damage caused by oxidative
stress and other vascular risk factors [13, 14]. As a result, it
could induce progressive damage to the peripheral sensory,
motor, and autonomic nervous systems [15]. Current treat-
mentofdiabeticneuropathyreliesonthecontrolofglycemic,
oxidative stress, and neural and vascular risk factors [13, 14],
but this does not fully prevent its occurrence or progression.
To date, except for rigorous glycaemic control, there are2 Oxidative Medicine and Cellular Longevity
few means to aﬀect or slow the natural progression of
DPN owing to limitations of the current inadequate drug
therapy [16]. Treatment of diabetic neuropathy is therefore
a major goal but, despite multiple attempts, no satisfactory
management is yet available. Consequently, the search for
substances to protect the nervous system from the degen-
erative eﬀects of diabetes has high priority in biomedical
research.
DFEs might be interesting since they have been recently
identiﬁed as promising neuroprotective agents in several
models of neurodegeneration [17]. Recent ﬁndings suggest
that antioxidant agents might exert neuroprotective eﬀects
and may be promising in therapy. Several dietary supple-
ments have been reported to have strong antioxidant eﬀects
and reduce neurological deﬁcits in aged animals [18]. One
of the dietary supplements is date fruit which has great
importance from nutritional and economic points of view
a n di ti sc o m p o s e do faﬂ e s h yp e r i c a r pa n ds e e d[ 19]. The
importance of the date in human nutrition comes from
its rich composition of carbohydrates, salts and minerals,
dietaryﬁbers,vitamins, fattyacids,aminoacids,andprotein.
In many ways, date may be considered as an almost ideal
food [20]. In addition, the date palm fruit possesses many
useful properties such as antioxidant and antimutagenic
[21], antibacterial [22], antifungal [23], antitumoral [24],
andgastrprotective[25]properties.Meanwhile,datefruithas
various neuroprotective agents such as melatonin [26]a n d
polyphenolic compounds [19].
According to recent studies, by Asadi-Shekaari et al. and
Panahi et al., DFE signiﬁcantly inhibited neuronal damage
induced by cerebral ischemia [17, 27]. Also they resulted that
the eﬀectiveness of DFE in focal cerebral ischemia is most
probably is due to its antioxidant property [17].
We have assessed whether the use of DFE has neuro-
protective eﬀects against STZ-induced diabetic neuropathy
at the neurophysiological, behavioral, and neuropathological
levels. STZ, which induces type 1 diabetes mellitus when
delivered to rats, is a useful etiological model for study-
ing complications caused by diabetic hyperglycemia [28].
Reduced nerve conduction velocity was found by numerous
authors in STZ-diabetic rats [29, 30]. The reduction of Na+,
K+-ATPase activity, together with the decrease in NCV, is the
hallmark of diabetic neuropathy [31].
We were interested in investigating the eﬀects of DFE-
enriched diets on the development of diabetic neuropathy
in STZ-induced diabetes in rats. We decided to investigate
the eﬀect of DFE-enriched diets speciﬁcally on MNCV,
behavioral activities, and pathology in STZ-induced diabetes
in rats.
2.MaterialsandMethods
2.1. Drugs and Reagents. To prepare DFE, fresh date fruit
was prepared from Bam town orchards, Kerman province
(South East of Iran). The kernel was removed and 100gr of
datewasimmersedin1000mL/distilledwaterfor48hours.It
was then mixed completely in a mixer and then the mixture
was centrifuged at 4000rpm at 4◦C for 20 minutes. After
sedimentation, the supernatant part was used for gavages.
Streptozotocin was purchased from Sigma-Aldrich. Blood
glucose kits were purchased from the Roche Company,
Germany.
2.2. Animals and Experimental Protocols. The care of lab-
oratory animals followed the guiding principles for care
and use of laboratory animals of the Neuroscience Research
Center of Kerman Medical University and the study protocol
was approved by the animal ethics committee of this
institution (Code: EC/KNRC/88-15). This study was carried
out on male rats of Wistar breed weighing 250 ± 20g.
During the study period, experimental animals were given
standard pellet diet and water ad libitium, kept in the
laboratory animal house under speciﬁc pathogen-free (SPF)
and constant temperature (25 ± 1◦C) conditions and a 12h
light-dark cycle (lights on at 06:30h). Special care was taken
to minimise animal suﬀering and to reduce the number
of animals used to the minimum required for statistical
accuracy.Animalswereacclimatisedtolaboratoryconditions
before the tests. All experiments were carried out between
09:00–13:00h.
Diabetes was induced by intraperitoneal injection of
45mg/kg freshly prepared STZ dissolved in 0.1mol/L Citrate
buﬀer (pH 4.4). At the end of the ﬁrst week after STZ
injection, blood sugar measurements were taken for diag-
nosing diabetes induction using tail’s vein blood (by ACCU-
CHEK-ACTIVE kit made by Roche, Germany). Rats with
fasting blood glucose levels over 200mg/dL were used in
the experiments [32]. The animals were divided into four
groups: the ﬁrst group consisted of nondiabetic animals.
Age- and weight-matched male Wistar rats that had not
been made diabetic were used as controls. The second, third,
and fourth groups consisted of diabetic animals. The second
group was as diabetic control group (sham). The third
a n df o u r t hg r o u p sw e r ep r e t r e a t e dw i t hD F Ea n dv e h i c l e
(4mL/kg/day, orally). Each group consists of 8 rats. In this
study, to prevent diabetic neuropathy, DFE (4mL/kg, daily
as gavage) was used for a period of six weeks, after rats
were conﬁrmed diabetic. Similarly to the DFE group, the
vehicle group also received distilled water (4mL/kg, daily as
gavage) from the end of the ﬁrst week for a period of six
weeks.
2.3. Physiological Measurements. Six weeks after starting
intervention,thehorizontalandverticalactivitiesofthemale
r a t sf r o me a c hg r o u pw e r em e a s u r e di na no p e nﬁ e l dw i t h
a computerized Ethovision software (version 3.1), a video
tracking system for automation of behavioral experiments
(Noldus Information Technology, The Netherlands). Black
wooden box (45 × 45cm, height: 50cm) was used. Rats
were placed individually in the center of the test box. After
that, the following behavioral parameters: total distance
moved (TDM, cm), total duration mobility and immobility,
and frequency of rearing (as a measure of vertical activity)
and grooming (rubbing the body with paws or mouth and
rubbing the head with paws) in the open ﬁeld were analyzedOxidative Medicine and Cellular Longevity 3
Table 1: Body weight and blood glucose levels of all groups.
Animal group Body weight(g) Blood glucose (mg dL−1)
Before STZ injection End experiment Before sacriﬁce
Control (8) 265 ±4.22 286.25 ± 5.32 106.25 ±4.16
Sham (9) 261.25 ±2.95 220 ±5.01∗∗∗∗ 306.25 ±19.45∗∗∗∗
Vehicle (8) 262.5 ±2.67 219.75 ± 5.14∗∗∗∗ 333.75 ±30.11∗∗∗∗
DFE (8) 266.25 ±3.75 247.25 ±3.85∗∗†† 288.87 ±24.17∗∗∗∗
Mean ± SEM (n = 8).
∗∗∗∗P < 0.0001 versus control, ∗∗P < 0.01 versus control, ††P < 0.01 versus sham.
for 5min [33]. Mean values (±S.E.M.) were calculated for
each and expressed as percent change versus control.
2.4. Nerve-Conduction Velocity Measurements. Slowing of
sensory nerve conduction velocity (SNCV) and motor nerve
conduction velocity (MNCV) was shown to develop within
the ﬁrst month of the onset of hyperglycemia in STZ-
diabetic rats [34–36]. Six weeks after the onset of hyper-
glycemia the animals were anesthetised with 50/20mgkg—
ketamine/xylazine i.p. injection to prevent discomfort and
then backs of rats were shaved. During the study, rectal
temperature was maintained at 37◦C to ease animal stress
from anesthetic. In a temperature-controlled environment
(25 ± 1◦C), small incisions were made in the right sciatic
notch and ankle. Sciatic-tibial motor MNCV was measured
by stimulating proximally at the sciatic notch and distally
at the knee via bipolar needle electrodes (PowerLab/ML856;
AD Instruments, Sydney, NSW, Australia; frequency 20Hz,
duration 0.1ms, amplitude 1.5V, sampling 20k/s) [37–39].
After single stimulus the compound muscle action potential
was recorded from the ﬁrst interosseous muscle of the hind-
paw by unipolar pin electrodes. The recording was a typical
biphasic response with an initial M-wave, which is a direct
motor response due to stimulation of motor ﬁbers. The
MNCV was calculated as the ratio of the distance (in mm)
between both sites of stimulation divided by the diﬀerence
between proximal and distal latencies measured in ms [37,
38]. Latency is measured from initial onset to maximum
negative peak.
2.5. Morphological Observations and Analysis of Sciatic Nerve.
In order to study morphological alterations resulting from
diabetic neuropathy, sciatic nerve was isolated and divided
into 2mm segments. They were ﬁxed immediately with
glutaraldehyde solution 2.5% in 0.1M Phosphate Buﬀer
Solution (PBS) for 24hr. The specimens were washed with
PBS for 3 times and post ﬁxed for 2hr in 1% tetroxide
osmium and dehydrated in graded concentration of ethanol
a n dﬁ n a l l ye m b e d d e di nE p o n8 1 2r e s i n .S e m i t h i ns e c t i o n s
(300nm) were stained with 1% toluidin blue and examined
by light microscopy. Ten ﬁelds of transverse sections were
morphometrically analyzed by computerized image analysis
system (Motic Images China e-kup Co.,Ltd). MFD, AD and
MSD were measured for each section. For ultrastructural
study, ultrathin sections (70nm) were stained with 1%
uranyl acetae and 2% lead citrate before viewing in Philips
EM300 (Philips, Eindhoven, Netherlands).
2.6. Statistical Analysis. The parametric data obtained by the
experiments have been analyzed by using SPSS version 17.0.
The quantitative data are expressed as the mean ± SEM.
Multiple comparisons were performed among experimental
groups by one-way analysis of variance (ANOVA) followed
by Tukey-Kramer post hoc test. P<0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Metabolic Characteristics. In the diabetic groups, the
plasma glucose concentrations at the end of the ﬁrst week
were 296.19% greater than those of control group (P<
0.0001). All diabetic rats showed high blood glucose and
marked impairment of growth at the end of the 7th week
after STZ injection. As shown in Table 1,b o d yw e i g h to f
7th-week diabetic rats was signiﬁcantly lower than normal
control rats. Treatment with DFE (six weeks) did not
signiﬁcantlyaﬀectthebloodglucoselevelsindiabeticratsbut
there was a signiﬁcantly diﬀerence in weight gain compared
to the sham group (P<0.01).
3.2. Eﬀects of DFE on Open Field Test. In the assessment
of diabetic neuropathy on the explorative activity of rats
in an open ﬁeld behavioral test, TDM, mobility, rearing
and grooming frequency were signiﬁcantly decreased in
sham group compared with the control group, but there
were no signiﬁcant diﬀerences between control, sham, and
DFE groups in time spent either in the centre (the most
anxiogenic area) or in the perimeter of the open ﬁeld.
Analysis of the TDM and mobility showed that DFE group
rats travelled signiﬁcantly more than rats in the sham group
(P<0.05) in the central and peripheral arenas. Rearing
frequencysigniﬁcantlyincreasedintheDFEgroupcompared
with the sham group (P<0.05), while grooming frequency
decreased signiﬁcantly in all of diabetic groups compared
with control group (P<0.05); see Figure 1.
3.3. Eﬀects of DFE on MNCV. Seven weeks after STZ
injection, the sciatic MNCV of rats in the sham group
(38.50 ± 2.06m/s) compared with that in the nondiabetic
control group (51.36 ± 3.5m/s) was signiﬁcantly slower by
approximately 133.4%. The MNCV in diabetic rats treated
withDFEshowedastatisticallysigniﬁcantincreasecompared
with that of diabetic rats in the sham group (P<0.05)4 Oxidative Medicine and Cellular Longevity
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Figure 1: Eﬀect of Date fruit extract on explorative behavior of rats in open ﬁeld test. (a) Rearing frequency:
∗∗P < 0.01 compared with
the control group,
†P < 0.05, compared with the DE group. (b) Grooming frequency:
∗P < 0.05 compared with the control group and (c)
TDM:
∗∗P < 0.01 compared with the control group,
†P < 0.05 compared with the DE group. (d) Mobility duration:
∗P < 0.05 compared
with the control group. Data are the Mean ± SEM.
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Figure 2: Eﬀect of Date fruit extract on motor nerve conductive
velocity (MNCV) in rats. Data are the Mean ± SEM.
∗P < 0.05
compared with the control group;
†P < 0.05, compared with the
DE group.
(Figure 2). The sciatic MNCV for rats in the DFE group did
not diﬀer from the control group.
3.4. Eﬀects of DFE on Morphological Changes of Myelinated
Nerves. Light microscopy study of sciatic nerves sections
showed the normal structure and morphology of myelinated
ﬁbers in the control group. In the sham and vehicle
groups, some abnormalities including increased numbers of
mast cells, edema, and myelin sheath splitting were seen
(Figure 3). Increasing in number of abnormal myelinated
ﬁbers was observed in Sham and vehicle groups. Pretreat-
ment of rats with DFE prevented all of these abnormalities to
a high extent. According to the data, MFD and AD of vehicle
and Sham groups were decreased in comparison to control
group. Pretreatment with DFE for six weeks signiﬁcantly
reversed each diameter reduction in diabetic rats (Table 2).
3.5.ElectronMicroscopy. Ultrastructuralevaluationofsciatic
nerves conﬁrmed the light microscopy ﬁndings. In addition,Oxidative Medicine and Cellular Longevity 5
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Figure 3: Light micrograph of transverse semithin sections of rat sciatic nerves. (a) Control group: myelinated nerve ﬁbers are in normal
structure and morphology. (b) Sham group: nerve ﬁbers show some abnormalitities such as myelin splitting (black arrow), mast cell
inﬁltration (M), and edema. (c) The DFE-treated group; the proportion of nerve ﬁbers with abnormalities was reduced ×1000 (Toluidin
blue staining).
Table 2:TheeﬀectofDFEonhistomorphometricparametersofrat
sciatic nerve.
Groups N MMFD (μm) AD (μm) MSD (μm)
Control 4 9.75 ±0.45 5.11 ±0.34 4.64 ±0.35
DFE 5 9.61 ±0.45 4.96 ±0.25 4.65 ±0.34
Sham 4 8.15 ±0.19∗ 4.09 ±0.15∗ 4.06 ±0.23
N: number of animals; MMFD: Mean-Myelinated Fiber Diameter; AD:
Axon Diameter, MSD: Myelin Sheath Diameter; Data are presented as Mean
± SEM. ∗P < 0.05 versus control.
some evidences of axonal degeneration such as mitochon-
drial swelling and disintegration of neuroﬁlaments were
observed under transmission electron microscope (Figure 4)
but degenerative, reactive, and proliferative of Schwann cells,
were not observed in any groups.
4. Discussion
In the present study, we evaluated the neuroprotective eﬀects
of a DFE diet on the development of experimental neu-
ropathy. According to our data, DFE (4mL/kg/day, orally)
has a beneﬁcial eﬀect in the prevention of experimental
neuropathy in male rats. In fact, we found a positive eﬀect of
DFE on electrophysiological marker of diabetic neuropathy
(MNCV) and open ﬁeld behavioural test. Furthermore,
we showed that DFE partially prevented the deﬁcit in the
pathological morphology of myelinated sciatic nerve ﬁbers
in diabetic rats.
Patterns of diabetes-related peripheral nerve abnormal-
ities can be categorised as distal symmetric sensory motor
neuropathy, autonomic neuropathy, and focal asymmetric
neuropathy. The most common pattern of injury is the
symmetricneuropathythatinvolvesdistalsensoryandmotor
nerves; small sensory ﬁber neuropathy is often prominently
aﬀected in the form of peripheral neuropathy of diabetic
mellitus. With increased duration of the disease, diabetic
subjects developed decreased sensations in the distal extrem-
ities that will result later in the loss of pain sensation and
ulcers. Treatment of diabetic neuropathy is a major goal,
but despite multiple attempts, no satisfactory management
is yet available. Moreover, clinical data have shown that
diabetic patients suﬀering peripheral neuropathy manifest
electrophysiologicalconductionabnormalities[40].Progres-
sive slowing of MNCV is an important characteristic related
to DPN. Our experiments showed that diabetic neuropathy
was induced by STZ at six weeks, as evidenced by slowing6 Oxidative Medicine and Cellular Longevity
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Figure 4: Electron micrograph of rat sciatic nerves. (a) Control group: myelinated ﬁber with normal structure and morphology. Axon
is in normal condition too. (b) Sham group: Myelinated ﬁber shows myelin splitting (white arrow). Loosening of myelin lamellae may
account for paler staining in the outer myelin sheath. Axonal degeneration was revealed with enlarged mitochondria (M) and neuroﬁlament
disintegration ((a) ×8900,(b) ×11500).
of NCV (Figure 2), in agreement with the literature [41].
We observed a 25% deﬁcit in MNCV in diabetic rats as
comparedtonondiabeticrats.Theseresultsareinaccordance
with other reports [37, 42–45]. In the present experiments,
diabetic rats treated with DFE exhibited amelioration of the
changes in MNCV.
Abnormalﬁbersundergoingaxonaldegenerativechanges
and myelin breakdown are reported to appear in the sciatic
nerveofSTZ-induceddiabeticrats[46].Wesawpathological
changes consisting mainly of axonal degeneration in the sci-
atic nerves in the diabetic rats after seven weeks of STZ injec-
tion (Table 2). In our current study, the eﬃcacy of the DFE
diet was also conﬁrmed by morphometric analysis showing
that axonopathy predominates over myelinopathy in STZ-
diabetic rats. We measured histomorphometric parameters
MMFD, AD, and MSD of sciatic nerves speciﬁcally. These
morphological indices are corrected by the DFE diet, giving
an axonal diameter distribution similar to that for the
nondiabetic animals.
Diabetes-induced slowing of conduction of large-
myelinated ﬁbers (LMFs) was accompanied by a decrease
in the proportion of the largest ﬁbers present in the sciatic
nerve. There is no marked ﬁber loss in short-term diabetic
rats, and the reduction in the proportion of large ﬁbers
was accompanied by a parallel increase in the proportion of
medium-sized ﬁbers, suggesting either delayed radial growth
of axons or atrophy of large axons. As axonal caliber is
a major determinant of conduction velocity, the capacity
of DFE to restore or maintain the proportion of large
myelinated ﬁbers in the sciatic nerve of diabetic rats reveals
a potential mechanism that could explain the eﬀect of
DFEonconduction.Physiopathologyofdiabetic neuropathy
includes activation of the polyol pathway, increases in
oxidative stress and advanced glycosylation end products,
perturbation in neurotrophism, and abnormalities in essen-
tial fatty acids metabolism [47]. Moreover, previous studies
have shown that free radicals induce oxidative stress under
diabetic conditions to hyperglycaemia [37, 44, 48, 49].
Oxidative stress causes vascular impairment leading to
decrease in nerve blood ﬂow, resulting in endoneurial
hypoxia and impaired neural function which may cause
MNCV slowing [37, 50]. On the other hand, according
to earlier investigations, LMFs preeminently determine
the compound MNCV [51]. Therefore, the decrease in
MNCV may be due to a decrease in LMFs or the arrested
developmental process of MFs. Moreover, the decrease in
MNCV could result from alterations in Na+,K +-ATPase
activity, the membrane environment, and histological dam-
age that particularly cause the loss of MLFs [52]. Treat-
ment of STZ-induced diabetic rats with DFE improved
MNCV, which could be due to preserved ﬁbres and axon
diameter.
Our ﬁndings, in accordance with earlier studies, indicate
that treatment with STZ increases morphological alteration
in the MFs of the sciatic nerve. The most abundant myelin
abnormality observed in our study was myelin infolding
in the axoplasm and ﬁber irregular shapes (Figure 3). Its
frequency is increased in aging and diﬀerent peripheral
neuropathies including peripheral diabetic neuropathy [53,
54]. In the present study some of the signiﬁcant eﬀects of
treatment with DFE are the reduction in the frequency of
axons with myelin abnormalities and loss of the proportion
of ﬁbers with irregular shapes induced by STZ treatment. In
agreement with earlier ﬁndings, our present results indicate
that a signiﬁcant decrease in the MMFD and MSD was also
detectedinSTZ-induceddiabeticrats[54].TreatmentofSTZ
rats with DFE is able to counteract the decrease in MMFD
and MSD in the sciatic nerve.
Electrophysiological and morphologic observations have
been conﬁrmed by the explorative behavior of animals ob-
served in the open ﬁeld test. In this test, TDM, rearing,
and mobility are signs of alterations in the animal’s spon-
taneous movements and explorative behaviour that showed
a signiﬁcant decrease in diabetes due to diabetic neuropathy.
In agreement with our results, signiﬁcantly decreased loco-
motor and exploratory activity (number of crossed ﬁelds,Oxidative Medicine and Cellular Longevity 7
rearings, and bar approaches) have been reported in STZ-
diabetic rats [55].
According to the results of the open ﬁeld test, in the
group that received DFE, as opposed to the sham group,
TDM, mobility, and rearing showed a signiﬁcant increase
and became close to the control group. Therefore, it can
be concluded that the neuroprotective eﬀect of DFE in
the prevention of diabetic neuropathy and consequently
the prevention of defects in explorative behaviour due to
diabetes is signiﬁcant.
As mentioned above, the pathology of diabetic neuropa-
thy also involves polyol pathway ﬂux, oxidative stress, accu-
mulation of advanced glycation endproducts, and micro-
vascular injuries. Oxidative stress is the cause as well as
sequel of almost all major pathophysiological pathways in
diabetic neuropathy. Growing attention has been paid to the
pathogenic roles of oxidative stress in diabetic neurological
complications. Reactive oxygen species (ROSs) are generated
by nonenzymatic protein glycation through a complex series
of chemical and cellular intermediates [56].
Recent studies showed that the Iranian dates are strong
radical scavengers and can be considered as a good source
of natural antioxidants for medicinal and commercial uses
[57]. This creates the impression that diﬀerent altered
mechanisms may be involved that the DFE could be having
an antioxidant and neuroprotective eﬀect [17, 21, 58]. Some
of the established neuroprotective constitituents of DFE are
as follows: melatonin, a potent antioxidant and free radical
scavenger [59]; Vitamin C, an accepted antioxidant agent
[60]; phenolic compounds which are contained in cinnamic
acids and distinctive ﬂavonoids with strong antioxidant
eﬀects [19]; magnesium, an antagonist of NMDA receptors
[61]; Vitamin B3, a water-soluble vitamin with neuropro-
tective properties [62]; manganese, a free radical scavenger;
and selenium, an antioxidant factor with synergic eﬀects
with vitamin C [63]. Therefore, the possible mechanism that
maybe responsible for DFE protection against neuropathy
is inhibition of oxidative damage due to ROS as indicated
by studies in STZ-diabetic rats treated with DFE. However,
it seems that the neuroprotective eﬀect of DFE cannot be
mediated by an improvement in the symptoms of diabetes
because there is no change in the hyperglycaemic state of
diabetic rats.
Although the animals in the nondiabetic control group
consumed the diet as much as diabetic groups, the diﬀerence
of weight gain among them was signiﬁcant (Table 1). As the
total energy available from protein, fat, and carbohydrate did
not diﬀer between control and sham groups, the same intake
of diet suggests that STZ-diabetic rats cannot suﬃciently
utilize the energy available from their diet. As in the other
diabetic animals, the DFE-treated diabetic animals lost body
weight and remained hyperglycaemic. Although the body
weight gain of the DFE group was better than other diabetic
groups, we can say that the eﬀects of DFE treatment on nerve
function in diabetic rats were not due to a global ameliora-
tion of the diabetic condition. Nevertheless, the protective
mechanism and connected factors are not known exactly but
the synergic eﬀect of diﬀerent antioxidative components of
DFE may give a reason for its neuroprotective mechanism.
Supplementary investigation should be designed to make the
exact mechanism clear.
To sum up, our study shows that treatment with DFE
can decrease behavioral, neurophysiologic and pathological
alterations induced by diabetes in the peripheral nerves of
rats and that an antioxidant-related mechanism contributed
to the improvement of diabetic neuropathy.
5. Conclusion
We found that DFE-diet intake in STZ-induced diabetic rats
provided protection against deterioration of the peripheral
nerve. We conclude that antioxidative property is one of the
major proﬁles that is implicated in neuron protection. Thus
our ﬁndings suggest that this compound may be considered
as a potential preventative approach for peripheral diabetic
neuropathy.
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